Deucravacitinib Long-term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 6, p. s422, 2024. DOI: 10.25251/skin.8.supp.422. Disponível em: https://skin.dermsquared.com/skin/article/view/3089. Acesso em: 18 may. 2025.